COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Phase 1 Study for Safety and Tolerability of HL036

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02717208
Recruitment Status : Completed
First Posted : March 23, 2016
Last Update Posted : December 9, 2016
Information provided by (Responsible Party):
HanAll BioPharma Co., Ltd.

Brief Summary:
To evaluate the safety, local tolerability and pharmacokinetic characteristics after administration of eye-drop HL036 in healthy Korean male volunteers

Condition or disease Intervention/treatment Phase
Dry Eye Biological: HL036 Biological: Vehicle Phase 1

Detailed Description:
A total of 10 subjects will be dosed in each group with subjects randomized 8:2 to HL036 or placebo. Three of 10 subjects will be randomized to the sentinel dosing in each group. A safety data review as masking will be performed for 3days prior to the other subjects treatment. Treatment of high dose will proceed following a review of safety data from low dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety, Local Tolerability and Pharmacokinetic Characteristics After Administration of Eye-drop HL036 in Healthy Korean Male Volunteers (Phase I)
Study Start Date : February 2016
Actual Primary Completion Date : June 2016
Actual Study Completion Date : June 2016

Arm Intervention/treatment
Active Comparator: HL036 0.5mg/ml
Administration : 2 times per day for one day
Biological: HL036
Biological: Vehicle
Active Comparator: HL036 5mg/ml
Administration : 2 times per day for one day
Biological: HL036
Biological: Vehicle

Primary Outcome Measures :
  1. Adverse Events [ Time Frame: 1 week ]

Secondary Outcome Measures :
  1. Peak Plasma Concentration (Cmax) [ Time Frame: 24 hours ]
  2. Area under the plasma concentration versus time curve (AUC) [ Time Frame: 24 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Subjects who listened to the description about characteristics of this clinical trial and signed the IRB approved consent form before the whole screening tests
  • Healthy Korean males volunteers who are 20 to 50 years old at screening procedure

Exclusion Criteria:

- Subjects who have a history of tuberculosis or have a positive Quantiferon Test

  • Subjects who have treated live vaccine within 8 weeks prior to the first day of dosing or have a plan to treat it before the end of study
  • Subjects who have presence or history of significant hepatic(including hepatitis B or C) , renal, neurological, immunological, respiratory , endocrine or hemato•oncology, cardiovascular, psychiatric disease
  • Subjects who have presence or history of ophthalmological examination by the following

    ① History of ocular disease including keratitis, uveitis, retinitis, dry eye, strabismus or had suspected symptoms or signs

    ② Subjects who are under 20/40 of corrected visual acuity at screening

    ③ Subjects with a history of ocular surgery ( including subjects who had laser surgery in the previous 6 month from screening)

    ④ Subjects who had contact lens wear within 1 month or had side effects after wearing, unwilling to discontinue wear during the study period

    ⑤ Abnormalities following other ophthalmological examination

  • Subjects who have a history of allergy to anti-TNF drug(infliximab, adalimumab, etanercept) or any similar product
  • Subjects who had a history of drug abuse or a positive of drug abuse at urine test
  • Subjects who have taken any prescribed drugs, herbal agents within 2 weeks or who have taken any over-the-counter (OTC) drugs including artificial tears or vitamins within 1 week prior to the first day of dosing (Investigators will determine his eligibility by considering the effect of the drug on his safety or pharmacokinetic results in case other inclusion/exclusion criteria is satisfied.)
  • Subjects who have participated in another clinical trial or bioequivalence research with an IP within 3 months prior to the first day of dosing.
  • Subjects who donated whole blood within 2 months or component blood within 1 month or who are donated within 1 month prior to the first day of dosing.
  • Subjects who have currently drinks in excess of 21 units per week(1 unit = 10 g of pure alcohol) or would not be able to stop drinking alcohol during the study
  • Subjects who have smoked in the 6 months or has used nicotine product or would not be able to stop smoking during the hospitalization Subjects who planned pregnancy or cannot use established contraceptions (e.g. infertility operation of the subject or partner, intrauterine contraceptive device of the partner, barrier contraception, diaphragm or condom use in combination during the test
  • Subject who are judged as inappropriate for participating in the clinical trial by researcher because of causes including the test result of clinical laboratory

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02717208

Layout table for location information
Korea, Republic of
Seoul National University Hospital,Clinical Trial Center/ Clinical Research Institute
Seoul, Korea, Republic of, 110-744
Sponsors and Collaborators
HanAll BioPharma Co., Ltd.
Layout table for additonal information
Responsible Party: HanAll BioPharma Co., Ltd. Identifier: NCT02717208    
Other Study ID Numbers: HTR15I_1
First Posted: March 23, 2016    Key Record Dates
Last Update Posted: December 9, 2016
Last Verified: February 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided